Leadbio Completes Tens of Millions RMB Series A+ Financing to Advance Regenerative Medicine and Small-Diameter Bioengineered Vascular Grafts

On June 12, 2024, LEADBIO (Hangzhou) Biotechnology Co., Ltd. (hereinafter referred to as "LEADBIO") completed byHangzhou Tasly New Track Equity Investment Partnership (Limited Partnership)LEADBIO Completes Tens of Millions of Yuan in A+ Round Financing, Following the A Round Completed at the End of 2023.

The funds from this round of financing will be mainly used for the clinical advancement of existing products and the research and development of new indications for coronary artery bypass artificial blood vessels, accelerating the progress of multiple preclinical studies.Promote LEADBIO's R&D and Innovation in the Field of Regenerative Medicine。

LEADBIO was founded in February 2019 with the mission of "Applying technology, Innovating healthcare." It is committed to the research and development of tissue-engineered artificial organs and organ preservation products that can replace or repair human tissues and organs, aspiring to become a global leader in regenerative medicine R&D and manufacturing. Adhering to the vision of "Innovating for life," LEADBIO will fully utilize this funding to accelerate product development, clinical trials, and market expansion, providing more and better tissue-engineered artificial organs and organ preservation products for patients worldwide.

Mr. Wang Chen, Managing Partner of Tasly CapitalIndicates: Artificial blood vessels, especially small-caliber artificial blood vessels, present significant technical challenges and address substantial unmet clinical needs in applications such as arteriovenous fistulas for renal dialysis and coronary artery bypass grafting. Small-caliber artificial blood vessels must balance short-term vascular access with long-term patency while meeting clinical usage requirements, including biocompatibility and other general criteria. We believe that at this stage, bioengineered artificial blood vessels produced using novel biodegradable biomaterial scaffolds, cell culture, and decellularization processes—combined with technologies like regenerative medicine, functional biomaterials, and tissue engineering—are the most promising solutions to achieve these goals.Clinical use requirements.In the future, this type of product can also be combined with the development of gene editing and stem cell technology to further upgrade and improve product performance by inducing factors to stimulate endogenous stem cells.. As a leading company in this field in China, LEADBIO, under the leadership of Teacher Kong Deling's team, has accumulated substantial experience and technical expertise. We are fortunate to have invested in LEADBIO and are attracted by the scientific, objective, and rigorous corporate culture of Teacher Kong’s team. We will spare no effort to support LEADBIO in completing small-caliber artificial blood vessel products that meet clinical requirements as soon as possible, benefiting a wide range of patients. We will also continue to support LEADBIO in advancing and upgrading in this field, helping it lead the development of the industry.

Relying on the industrial resources of its shareholder, Tasly Holding Group, and adhering to the concept of industrial investment, the company persists in the 4D investment strategy. It focuses on building an ecosystem for the pharmaceuticals, medical devices, diagnostics, and digital health industries around disease areas such as cardiovascular, oncology, metabolism, and gastroenterology, aiming to support the development of startups and growth-stage enterprises. Since its establishment in 2007, the company has managed a scale exceeding 10 billion yuan, with seven RMB funds and three USD funds successively; it has invested in over 100 projects cumulatively, exited more than 30 projects, among which 16 projects have successfully gone public through IPOs. These include well-known industry enterprises such as Innovent Biologics, Leadbio, CARsgen Therapeutics, I-Mab, Berry Genomics, Xinwei Medical, and Northland Biotech.